Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. - Wikidata - awgldk - TriplyDB

Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.

Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.

http://www.wikidata.org/entity/Q49017971

about

Role of positron emission tomography for the monitoring of response to therapy in breast cancer Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?PET/CT in Oncology: Current Status and Perspectives.Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study Predictive value of initial FDG-PET features for treatment response and survival in esophageal cancer patients treated with chemo-radiation therapy using a random forest classifier.The accuracy of (18)F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review.A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.Quantitative Evaluation of Therapeutic Response by FDG-PET-CT in Metastatic Breast Cancer HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment Future directions for monitoring treatment responses in breast cancer.18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.Impact of partial-volume correction in oncological PET studies: a systematic review and meta-analysis.Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence.Present and future role of FDG-PET/CT imaging in the management of breast cancer.¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.The influence of different signal-to-background ratios on spatial resolution and F18-FDG-PET quantification using point spread function and time-of-flight reconstruction.Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome.Robustness of intratumour ¹⁸F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma.Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting.Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients.Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy.Tumour and lymph node uptakes on dual-phased 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography correlate with prognostic parameters in breast cancer.The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy.HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.

P2860

Q28080621-5306A828-75B1-4AEC-B3FB-B48CD3C39837 Q33576007-2FC5F517-B8D0-4F0E-A088-08935EAE47AE Q33665109-6BBD658D-44C1-4E29-92E4-322CC4EC10E7 Q33780956-DEFD3DA2-64D5-4C83-970B-9BF71889D248 Q35539538-F28102ED-6F33-4F7E-A346-F58EC62BD23F Q36304217-24426E77-8AB1-4DD6-8528-48634E279702 Q36364739-BF05F3B2-742D-4217-B947-8D0A757DC5E7 Q36533964-4DD6F440-1C4D-4B8D-B901-16301B112481 Q36557319-16423546-2010-4FFD-900D-30A771AD28AF Q36883389-09BFC427-7123-47F3-B814-E4B61576B518 Q37185872-A827C316-4B64-4C5A-94DB-9373DBAA6684 Q37435201-6CA9DB02-CFD5-468B-9176-B933B00B8E3F Q37566580-EEA1A76B-D64A-4579-BC58-B0F60DA65745 Q38426713-491211E9-E2D8-496D-AB53-CADE8FB2BDC0 Q38446353-11E78196-4270-489D-A282-A816F69AC860 Q38641832-0EC30896-2ACB-48F2-9E2E-1489BB0A767A Q38663416-4B8BC13E-DCD8-46F2-8EFA-2C78E94EE59C Q38687620-3959465E-32DD-4EAC-B590-15F11E033BCD Q38693888-1D0A8323-CA84-4206-B1CF-EF6A264BCC94 Q40392850-879A4FEA-0771-422E-8270-FAF01434150B Q41507039-693F645E-CA1C-4803-A6B4-EEB6B28ACF3F Q43491287-A78CEA36-A7A9-4265-BC8D-547C72E2D73D Q43753631-AC36C160-A94B-4929-8C2D-2D7535DACD99 Q47959144-24C2C76E-5F60-4792-9622-596F30E00263 Q48047542-7096A227-D0DC-4158-A740-EA30BC25890F Q49386829-449CA5D2-9A5F-4791-8F53-6031ACD42A0A Q50172829-C05C24EB-3730-4EA4-AC39-7F25C32FF051 Q53043935-51DCA5DD-1873-4EDE-AE55-55A1397736AD Q53063063-5AEC5BB8-97BB-44E6-B3E5-BECE13E4761E Q53074363-1AFC5FF5-D341-457E-A09E-9EE866804C1D Q54316674-F02D8655-52D4-4BA1-BC58-CFBA814E1013 Q55286904-C78058D3-0C0A-4367-A155-74F9D6F1D00C

P2860

Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.

http://www.wikidata.org/entity/Q49017971

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Comparison between 18F-FDG PET ...... chemotherapy in breast cancer.

@en

Comparison between 18F-FDG PET ...... chemotherapy in breast cancer.

@nl

type

label

Comparison between 18F-FDG PET ...... chemotherapy in breast cancer.

@en

Comparison between 18F-FDG PET ...... chemotherapy in breast cancer.

@nl

prefLabel

Comparison between 18F-FDG PET ...... chemotherapy in breast cancer.

@en

Comparison between 18F-FDG PET ...... chemotherapy in breast cancer.

@nl

P1433

Q49017971-2A418078-E511-4871-86BF-DFB3D16308AC

P1476

Q49017971-DF117E21-1AAB-4292-8523-712D1E6FA114

P2093

Q49017971-3FE5F701-B3E2-46F3-BA3B-53837335BC5C

Q49017971-4CAACD54-99A1-43D5-8886-652D1A641796

Q49017971-542AFA91-822A-4BB8-8B88-6EDAC2740579

Q49017971-855B4269-54F9-4BC1-B2C8-880E19181F90

Q49017971-BCC5820C-759C-448F-AD76-BCB6182871F7

Q49017971-C07DDFFB-0211-4DDB-932C-185FBB767AB3

Q49017971-C7047A58-A972-4A22-A36F-E647D1248A85

Q49017971-CA519A87-5D75-40C9-BFA1-C0427C933F71

Q49017971-EAC5BCE9-06C4-4FFC-AFCC-FC1F5AEB3A66

P304

Q49017971-2B18FEEF-FE26-449D-937E-0DD58F22FA6B

P31

Q49017971-B6C87F74-CDF8-45D4-A2BF-B5ABFD1773B2

P356

Q49017971-F47EEB99-E80A-45B4-999D-ACA7F38C4EF4

P407

Q49017971-25EF3E31-3E0D-4368-8D54-74ED9CEBE67F

P433

Q49017971-23CFB7A5-3FDF-4AEB-B52E-8CF39C0D45FA

P478

Q49017971-176DE43A-D65D-4DE0-9F8A-C7FA6C296CB4

P577

Q49017971-A6E58F6C-91AC-44DE-8869-BBE4131F1E3A

P5875

Q49017971-3F76AFB4-31B1-4401-91D8-428ADD17942C

P698

Q49017971-7CC03676-0782-4D32-89C7-C48FF92D9545

P921

Q49017971-F61A22EB-6949-485F-BFBF-D744C1C67EB7

P356

JNUMED.112.108837

P1433

The Journal of Nuclear Medicine

P1476

Comparison between 18F-FDG PET ...... chemotherapy in breast cancer.

@en

P2093

Anne de Roquancourt

http://www.w3.org/2001/XMLSchema#string

Antoine Martineau

http://www.w3.org/2001/XMLSchema#string

Catherine Cheze-Le Rest

http://www.w3.org/2001/XMLSchema#string

David Groheux

http://www.w3.org/2001/XMLSchema#string

Dimitris Visvikis

http://www.w3.org/2001/XMLSchema#string

Elif Hindié

http://www.w3.org/2001/XMLSchema#string

Marc Espié

http://www.w3.org/2001/XMLSchema#string

Mathieu Hatt

http://www.w3.org/2001/XMLSchema#string

Sylvie Giacchetti

http://www.w3.org/2001/XMLSchema#string

P304

341-349

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.112.108837

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234160317

http://www.w3.org/2001/XMLSchema#string

P698

23327900

http://www.w3.org/2001/XMLSchema#string

P921